TaiMed and AcedrA officially signed an exclusive license, commercialization, and distribution agreement for Trogarzo in the MENA region.
TaiMed and AcedrA officially signed an exclusive license, commercialization, and distribution agreement for Trogarzo in the MENA region.
TAIPEI, Oct. 16, 2023 /PRNewswire/ -- TaiMed Biologics, an innovation-driven biotech company dedicated to serving unmet healthcare needs, has announced favorable results and the successful completion of the sentinel group in its phase 1b/2a clinical study evaluating its groundbreaking new treatment for HIV — Long-Acting TMB-365/TMB-380 mAb Combination Maintenance HIV Therapy — initially unveiled at its investor conference on September 6. Following a professional assessment of dosing selection, the company has confirmed the dosages required for the future administration of the two-month combination therapy, thereby achieving its original goals for the sentinel group clinical trial.